Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) is sponsored by Advanced Research Projects Agency for Health (ARPA-H). A competitive Innovative Solutions Opening (ISO) seeking teams to develop trusted, autonomous clinical AI agents for continuous cardiovascular patient care and monitoring.
Official opportunity description and requirements excerpt:
An official website of the United States government The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Open Funding Opportunities Submission Resources and FAQs Commercialization Services ARPANET-H Innovation Network Other Transaction Community What is a Program Manager? Program Manager Application Agentic AI-Enabled Cardiovascular Care Transformation What if an FDA-authorized clinical agentic AI could provide safe and effective cardiovascular care to every American? Over 200,000 Americans die each year from preventable impacts of cardiovascular disease (CVD), the leading cause of death in the U.S. Despite spending almost half a trillion dollars on heart disease alone, the US experiences much worse outcomes than many other similar nations. Treatments for managing heart health with diet, exercise, and affordable medications are simple, inexpensive, and effective. Yet nearly half of American counties lack a cardiologist, meaning that many patients across the country are missing out on life-saving care and interventions. Clinical artificial intelligence (AI) agents could help fill this gap, but we don’t currently have a clear way to ensure they consistently operate safely and effectively at scale in real-world settings. The Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program aims to transform advanced cardiovascular disease management with an agentic AI system that can provide 24/7 holistic clinical care. ADVOCATE will support the development of clinical AI agents that can be trusted to autonomously adjust changes in appointments, medications, diet, and exercise. In parallel, ADVOCATE will support the development of a supervisory AI "overseer” to monitor clinical AI agents after they have been deployed in clinical practice to ensure their continued safety and efficacy. ADVOCATE's transformative goal is to create a first-of-its-kind, reliable, FDA-authorized clinical agentic AI system that serves around the clock as a new, digital member of the clinical care team. Together, these efforts will enable an integrated, holistic cardiovascular care platform to provide real-time guidance that patients and care teams can act on. The program will partner with health systems to successfully deploy the technology across diverse care environments—from major health systems to rural clinics and community settings. Harness the power of American innovation to quickly develop agentic AI that is safe, transparent, and effective in healthcare settings. Unleash the best technical experts across sectors to tackle a leading cause of death in the U.S. and accelerate pathways for regulatory and reimbursement approvals. Build
Extracted from the official opportunity page/RFP to help you evaluate fit faster.
An official website of the United States government The . gov means it’s official. Federal government websites often end in .
gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. Open Funding Opportunities Submission Resources and FAQs Commercialization Services ARPANET-H Innovation Network Other Transaction Community What is a Program Manager?
Program Manager Application Agentic AI-Enabled Cardiovascular Care Transformation What if an FDA-authorized clinical agentic AI could provide safe and effective cardiovascular care to every American? Over 200,000 Americans die each year from preventable impacts of cardiovascular disease (CVD), the leading cause of death in the U. S.
Despite spending almost half a trillion dollars on heart disease alone, the US experiences much worse outcomes than many other similar nations. Treatments for managing heart health with diet, exercise, and affordable medications are simple, inexpensive, and effective. Yet nearly half of American counties lack a cardiologist, meaning that many patients across the country are missing out on life-saving care and interventions.
Clinical artificial intelligence (AI) agents could help fill this gap, but we don’t currently have a clear way to ensure they consistently operate safely and effectively at scale in real-world settings. The Agentic AI-EnableD CardioVascular CAre TransfOrmation (ADVOCATE) program aims to transform advanced cardiovascular disease management with an agentic AI system that can provide 24/7 holistic clinical care.
ADVOCATE will support the development of clinical AI agents that can be trusted to autonomously adjust changes in appointments, medications, diet, and exercise. In parallel, ADVOCATE will support the development of a supervisory AI "overseer” to monitor clinical AI agents after they have been deployed in clinical practice to ensure their continued safety and efficacy.
ADVOCATE's transformative goal is to create a first-of-its-kind, reliable, FDA-authorized clinical agentic AI system that serves around the clock as a new, digital member of the clinical care team. Together, these efforts will enable an integrated, holistic cardiovascular care platform to provide real-time guidance that patients and care teams can act on.
Based on current listing details, eligibility includes: Nonprofits, universities, small businesses, and for-profit industry teams. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates $1,000,000 - $9,000,000 Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is February 27, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
Rural Communities Opioid Response Program (RCORP) - Impact is sponsored by Health Resources and Services Administration (HRSA). Funds community capacity building for prevention, treatment, and recovery services for substance use disorders in rural areas. Application snapshot: target deadline February 23, 2026; published funding information $200,000 - $1,000,000; eligibility guidance Rural organizations and communities addressing opioid response Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Bloomberg Initiative to Reduce Tobacco Use Grants Program is sponsored by Bloomberg Family Foundation Inc.. This program supports projects to develop and deliver high-impact, evidence-based tobacco control interventions in low- and middle-income countries. Funding focuses on policy reforms such as strengthening tobacco taxation, implementing smoke-free laws, advertising bans, and graphic pack warnings. It includes both 'Open Rounds' for broad policy work and a specific 'Tobacco Industry Interference' (TII) subset to counter industry tactics. Geographic focus: Low- and middle-income countries (Global) Focus areas: Public Health, Tobacco Control, Policy Reform Official opportunity description and requirements excerpt: Contact | Bloomberg Philanthropies Strengthening Local Arts Organizations Connecting Audiences to Culture Online or Onsite Advancing the Arts Around the World Collaborating with Cultural Funders Expanding College Access and Success Supporting Career and Technical Education Supporting Educational Institutions Supporting Sustainable Cities Driving Sustainable Finance Spurring Innovation in Cities Strengthening City Data to Improve Lives Promoting Healthy Food Choices Combating the Overdose Epidemic Increasing Access to Reproductive Health Care Promoting Cardiovascular Health Building Public Health Coalitions Strengthening Health Data Women’s Economic Development Perelman Performing Arts Center at the World Trade Center Charlotte and William Bloomberg Medford Public Library Goldman Sachs 10,000 Small Businesses English French German Spanish Portuguese (Brazil) Italian Korean Russian Hindi Japanese Chinese (Simplified) Chinese (Traditional) English French German Spanish Portuguese (Brazil) Italian Korean Russian Hindi Japanese Chinese (Simplified) Chinese (Traditional) Bloomberg Philanthropies is only as strong as its connections. Whether you have questions or want to get involved, we want to hear from you. Please use the following information or fill out the form below to contact us and we’ll do our best to send you a prompt response. If your inquiry involves a request for funding or partnership, please note Bloomberg Philanthropies works with existing partners on all of our key initiatives and does not make grants outside our focus areas or directly to individuals. Grant proposals are by invitation only and news on grants competitions are posted regularly on our website. Members of the media may contact communications@bloomberg.org . Choose Your Subject General Inquiries Grants Events Careers Arts Education Environment Government Innovation Public Health Bloomberg Associates Founder's Projects Please note grant proposals are by invitation only and we do not make grants outside our focus areas or directly to individuals. Top photo: Christo’s temporary sculpture in Hyde Park, London, “The London Mastaba,” located in Serpentine Lake, Hyde Park during summer of 2018. Application snapshot: target deadline February 25, 2026; published funding information $50,000 - $250,000 per year; eligibility guidance Government agencies and non-governmental organizations (NGOs) in low- and middle-income countries (LMICs) as categorized by the World Bank. Priority is given to countries with the highest tobacco use. Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
Application snapshot: target deadline February 27, 2026; published funding information $1,000,000 - $9,000,000; eligibility guidance Nonprofits, universities, small businesses, and for-profit industry teams.
Use the official notice and source links for final requirements, attachment checklists, allowable costs, and submission instructions before applying.
The program will partner with health systems to successfully deploy the technology across diverse care environments—from major health systems to rural clinics and community settings. Harness the power of American innovation to quickly develop agentic AI that is safe, transparent, and effective in healthcare settings. Unleash the best technical experts across sectors to tackle a leading cause of death in the U.
S. and accelerate pathways for regulatory and reimbursement approvals. Build trust with patients, doctors, and other stakeholders around patient-facing AI agents through rigorous testing and demonstrating measurable improvements in safety, outcomes, and equity.
Pave the way for AI technology to serve as a clinician-extender, first for advanced CVD and eventually for all chronic conditions. What ARPA-H needs to solve this problem ADVOCATE seeks leaders in the tech sector, academia, non-profit organizations, and small businesses to overcome the technical, regulatory, and market barriers holding back innovation in clinical agentic AI.
The program has three technical areas: development of a patient-facing clinical AI agent, a supervisory agent that ensures clinical AI agents’ consistent safety and effectiveness, and a scalable plan for integration into clinical workflows in healthcare organizations. Notice ID: ARPA-H-SOL-26-142 ARPA-H invites interested parties to review the solicitation, which is posted and maintained on SAM. gov.
The solicitation outlines the opportunity and its requirements, key dates and deadlines, submission documents and templates, evaluation criteria for submissions, and information on how to apply. Solution Summary Due: February 27, 2026 A summary is required to submit a full proposal.
Full Proposal Due: April 1, 2026 After submission of a solution summary, proposers will either be encouraged or discouraged from submission of a full proposal. It is strongly recommended that only proposers who are encouraged to submit a full proposal do so. Reminder: Dates are estimates and subject to change.
Please reference the solicitation for the most up-to-date information. Review Solicitation Details Ready to apply? To submit a Solution Summary, sign-in to the ARPA-H Solutions Portal .
Frequently Asked Questions Review responses to common questions about this funding opportunity asked by others in the proposer community. You can also ask a question. Review FAQs and Ask A Question This is an optional event for the proposer community to learn more about this opportunity, ask questions, and make connections.
This event is not intended for patients, patient advocates, the media, or general interest audiences. View the Proposers' Day recording View the Lightning Talk presentations This optional webinar for the proposer community was an additional chance to ask questions and get clarification on the ADVOCATE ISO. See the Special Notice ( ARPA-H-SN-26-148 ) for additional details.
ARPA-H anticipates that teaming will be necessary to achieve the goals of ADVOCATE. Prospective proposers are encouraged to form teams with varied technical expertise to submit a research proposal. To facilitate this process, we have created a teaming page where prospective proposers can share their profiles and learn more about other interested parties.
"What we are trying to achieve with ADVOCATE is a technology that can essentially serve as a clinician-extender: an autonomous agent smart enough to understand patients’ treatment needs, which can both provide certain care autonomously as well as engage the clinical team as needed." ARPA-H to revolutionize cardiovascular disease management with clinical agentic AI Freedom of Information Act Vulnerability Disclosure Policy
© 2026 Granted AI